Yes. The standard regimen is one drop in each affected eye once nightly. If only one eye requires treatment, the drop can be limited to that eye alone.
Iris colour change is a known, usually permanent effect of latanoprost. It does not affect vision, but you should discuss any concerns with your ophthalmologist, especially if the change is unexpected or pronounced.
Remove contact lenses before instilling the drop, wait at least 15 minutes, and then re-insert them. Some patients prefer to wear lenses after dosing to minimise irritation.
A single 2.5 ml bottle supplies approximately 50 drops (about 0.05 ml per drop). At one drop per eye per night, the bottle will last roughly 3-4 weeks.
It is generally safe after uncomplicated cataract surgery, but the operating surgeon may advise temporary discontinuation to reduce the risk of postoperative inflammation.
Yes, but the timing should be separated by at least 5 minutes. Use the “blink-and-wait” technique: apply the first drop, close the eye gently, then wait before instilling another medication.
Latanoprost’s systemic absorption is minimal, and no clinically significant interaction with oral antihypertensive drugs has been reported.
Evening dosing aligns with the natural circadian rise in IOP that occurs overnight, providing better IOP control during the early morning hours when pressure peaks.
In the United States, Xalatan is supplied in a 3 ml bottle with the same concentration. The UK version is a 2.5 ml bottle, but the dosing instructions remain identical.
Active uveitis is a contraindication because prostaglandin analogues may exacerbate intra-ocular inflammation. Once inflammation resolves, an ophthalmologist may reassess suitability.
Xalatan 0.005% is a brand-name ophthalmic solution that contains latanoprost as its active ingredient. Latanoprost belongs to the prostaglandin-analog class of eye-care medications and is approved in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) for the reduction of intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The product is supplied in single-use 2.5 ml bottles of sterile eye-drop solution.
Latanoprost is a synthetic analogue of prostaglandin F₂α. After instillation into the conjunctival sac, the drug penetrates the cornea and is hydrolyzed to its active acid form. The active metabolite binds to prostaglandin-F (FP) receptors in the ciliary body and trabecular meshwork, leading to:
These actions lower the pressure inside the eye, which helps prevent optic-nerve damage associated with glaucoma. The therapeutic effect typically begins within 12 hours of the first dose and reaches a plateau after about four to six weeks of consistent nightly use. Because the drug acts locally, systemic exposure is minimal.
Xalatan 0.005% is approved in the UK for the following indications:
Both conditions are managed by maintaining IOP at a level that reduces the risk of visual field deterioration. Xalatan is often prescribed as first-line therapy, especially when a once-daily dosing schedule is preferred.
Current peer-reviewed literature does not provide robust evidence for approved off-label uses of latanoprost in the UK. While some small studies have explored its role in secondary glaucoma types (e.g., pseudoexfoliative glaucoma), these applications remain investigational and should only be considered under specialist supervision.
These effects are generally mild, reversible on discontinuation (except iris colour change, which may be permanent), and do not require medical intervention.
Note: Patients should inform their ophthalmologist of all prescription drugs, over-the-counter products, herbal supplements, and vitamins before starting Xalatan 0.005%.
This article provides educational information about Xalatan 0.005% and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
